+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
+ Follow xFollowing xFollowing - Unfollow
The report on the Coronavirus test kits market in North America provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
In addition, the report also provides an up-to-date analysis regarding the current global market scenario and overall market environment. The market is driven by the regional outbreak of coronavirus and product innovations
The Coronavirus test kits market in North America analysis includes End User segmentationand Geographiclandscape. This study identifies fastrackapproval of diagnostic kits as one of the prime reasons driving the market growthin North America growth during the next few years.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The Corona Virus test kits market in North America covers the following areas:
Corona Virus Test Kits Market SizingIn North AmericaCorona Virus Test Kits Market Forecast In North AmericaCorona Virus Test Kits Market Analysis In North AmericaCompanies Mentioned
Related Reports onHealth Care Include:Coronavirus Test Kits Market by End-user and Geography - Forecast and Analysis 2021-2025: The coronavirus test kits market size will decrease by USD11.01 billion during 2021-2025,according to Technavio. Download PDF Sample
MRSA Testing Market by End-user and Geography - Forecast and Analysis 2021-2025: The MRSA testing market size has the potential to grow by USD 518.33 million during 2021-2025,according to Technavio. Download PDF Sample
Key Topics Covered:
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by End-user
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavio's in-depth research has direct and indirect COVID-19 impacted market research reports.Register for a free trial today and gain instant access to 17,000+ market research reports.Technavio's SUBSCRIPTION platform
About UsTechnavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
ContactTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: [emailprotected]Website: www.technavio.com/Report:https://www.technavio.com/report/coronavirus-test-kits-market-in-north-america-industry-analysis
SOURCE Technavio
Stars and Stripes is making stories on the coronavirus pandemic available free of charge. See more staff and wire stories here. Sign up for our daily coronavirus newsletterhere. Please support our journalismwith a subscription.
KAISERSLAUTERN, Germany The coronavirus is in retreat in Germany, top health officials said Friday, even as they warned that it could resurge again if people let down their guard too soon and businesses reopen too quickly.
The third wave seems to be broken, Health Minister Jens Spahn told reporters in Berlin. Infection numbers are going down again, but are still at a high level. And they are not going down equally fast everywhere.
The drop in cases happened largely because people in Germany took the warnings and restrictions seriously, reduced their personal contacts which was hard for everyone and avoided unnecessary travel, he said.
The weekly incidence rate for new infections across Germany fell to just under 126 cases per 100,000 inhabitants as of Friday, according to data posted on the website of Germanys infectious diseases agency, the Robert Koch Institute.
The number of new infections was down by 10,000 compared to two weeks ago, to 18,485 infections on Friday, RKI said.
But in the district of Kaiserslautern, which is home to Ramstein Air Base and a number of Army installations, the weekly incidence rate inched up Friday to 106 new cases per 100,000, compared to 100 per 100,000 the previous day, according to RKI.
Those data, however, didnt include the tens of thousands of Americans who live in the area. If they were factored in, the district would have been below the critical incidence rate of 100 new cases per 100,000 inhabitants per week, above which federally mandated restrictions kick in, including a 10 p.m. to 5 a.m. curfew, and a requirement to be tested and make an appointment before shopping for nonessential goods like shoes and clothes.
Counting the large American military community in the Kaiserslautern district, weekly incidence falls to around 91 new cases per 100,000 residents. District councillor Ralf Lessmeister and the mayor of Ramstein-Miesenbach, Ralf Hechler, have gone to court to try to have the U.S. military community included in the population tally.
In the Bavarian district of Neustadt an der Waldnaab, which includes the Grafenwoehr and Hohenfels training areas, numbers have fallen well below 100 and beer gardens are set to reopen starting Monday, officials have announced.
Honestly, thats super exciting, said Sgt. Luis Garcia with the 41st Field Artillery Brigade. Beer gardens are one of the greatest things I liked about Germany but I think they should also do quick COVID tests ... before people go in to have a drink.
Garcia is one of around 25,000 U.S. service members, civilian employees, contractors and their families who are based in the area, U.S. Army Garrison Bavaria says on its website. In total, more than 38,000 Americans affiliated with USAG Bavaria live in Germanys largest state.
Spahn said that when new infections fall below 100 cases per 100,000 people per week, and a city or district starts to ease restrictions, it should happen outside and be supported by tests.
New infections in Stuttgart, which is home to some 20,000 Americans affiliated with the military, were above 200 per 100,000 residents Friday. In Wiesbaden, they were at 134 infections per 100,000 people.
Ninety percent of recent cases in Germany were caused by coronavirus variants, which are much more infectious than the strain of the virus that predominated during the first wave, RKI head Lothar Wieler said.
If people stop wearing masks and stand at least three feet from others, one person who is infected with a variant could spread it to four others, Wieler said, illustrating how easily the virus could gain ground again if people let down their guard.
Stars and Stripes reporters Immanuel Johnson and Marcus Kloeckner contributed to this report.
zeitvogel.karin@stripes.comTwitter: @StripesZeit
A customer picks up a slice of cake at Cafe Susann in Kaiserslautern, Germany, during the first wave of the coronavirus, May 8, 2020. A year later, Germany was in a third wave of the virus and most eateries were still doing takeout only. KARIN ZEITVOGEL/STARS AND STRIPES
article continues below
Updated May 7, 2021 at 3:44 PM ET
Dr. Nancy Messonnier, the top respiratory disease official at the Centers for Disease Control and Prevention who was among the first to warn the American public about how much the pandemic would change everyday life, is stepping down from the agency.
She made the announcement in an email to staff Friday, as first reported by The Washington Post and confirmed by NPR. Her last day will be May 14.
My family and I have determined that now is the best time for me to transition to a new phase of my career, she wrote.
Messonnier had worked for the CDC for more than 25 years, ascending to her role as director of the National Center for Immunization and Respiratory Diseases in 2016. Since late 2019, she had headed the agencys COVID-19 task force, but she was recently reassigned from that post.
Dr. Messonnier has been a true hero, and through her career in terms of public health shes been a steward of public health for the nation. Over this pandemic and through her many-decade career, shes made significant contributions, and she leaves behind a strong force of leadership and courage in all that shes done, CDC chief Dr. Rochelle Walensky said at a Friday briefing of the White House COVID-19 Response Team, declining to comment further.
Messonnier rose to public prominence for her warnings about the coronavirus in early 2020.
At a White House press briefing in late February, when the country had barely more than a dozen reported cases of the virus, Messonnier warned that community spread would be likely and that disruption to everyday life might be severe.
Its not so much a question of if this will happen anymore, but rather more a question of exactly when this will happen and how many people in this country will have severe illness, she said.
At the time, her words about the pandemic were among the strongest yet from the Trump administration, which was still publicly downplaying the severity of the situation. Stocks tumbled. The Wall Street Journal later reported that then-President Donald Trump threatened to fire Messonnier shortly afterward.
The next day, Trump announced he was putting the vice president in charge of the governments response and famously predicted that what were then 15 reported cases within a couple of days is going to be down to close to zero.
Messonnier did not appear at any further White House briefings, though she continued to make other public appearances, including briefings at the CDC and an interview with NPR.
In her resignation announcement, Messonnier said she will become the executive director for pandemic and public health systems at the Skoll Foundation, a private organization founded by Jeff Skoll, the first president of eBay. The Skoll Foundation is an NPR sponsor.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
British Prime Minister Boris Johnson said on Friday the government needed to handle carefully the emergence of new coronavirus strains first found in India which have since started to spread in the United Kingdom.
"I think we've got to be very careful about that. We're doing a huge amount, obviously, to make sure that when we do find outbreaks of the Indian variant that we do surge testing, that we do door-to-door testing," he told reporters.
Our Standards: The Thomson Reuters Trust Principles.
TOMPKINS COUNTY, N.Y.The tone shift from the Tompkins County Health Department regarding the COVID-19 vaccine over the last six weeks or so has been stark. It has moved, gradually then more quickly, from an enthusiastic but measured push, hamstrung somewhat by supply provided by New York State, to a more frenetic effort featuring walk-in appointments and mass clinics throughout the county to reach more rural populations.
That shift is indicative of the county nearing a point that public health officials have warned about, though when exactly it would come has only recently become clearer: the vaccine plateau, or in other words, the point at which everyone who wants to get the vaccine has received it, and how far from the stated herd immunity figure of 75 percent that will be (though that appears to be an ominously moving goalpost).
Now, it seems Tompkins County has reached that stage. With 61.2 percent of county residents having received at least their first vaccine dose as of May 7, and 49.2 percent being fully vaccinated, the rate of people receiving a vaccination has greatly slowed since early April.
To further illustrate that: from April 1 to April 7, 5,839 Tompkins County residents received at least their first vaccine dose (April 1 is the first available data point of that kind). After one other high week, that weekly number has declined each subsequent week, until from April 30 to May 6, just 1,185 residents received at least their first dose.
Part of that is a naturally dwindling number of people who need the vaccine (since theyve already received it), but a group remains that simply doesnt want it and wont take it. Even with the recent slowdown, Tompkins County still leads municipal counties in the state in vaccine rates.
According to Public Health Director Frank Kruppa, the county has officially moved to the point where local supply is outpacing demand. Looking on the bright side, though, Kruppa said he had been impressed by the initial uptake of Tompkins County residents, who had surpassed his expectations that a plateau would likely occur closer to 45 or 50 percent vaccinated.
Since the beginning of the year, I had been thinking that mid-April we were going to make the shift to having more vaccines than people to vaccinate, and thats about when it happened, Kruppa said. Whats been a positive surprise is the number of people weve been able to reach in that timeframe. () Weve still got a ways to go, were still working to get the vaccine into more people, but so far we can be happy about our success.
While supply was the issue early on, access has moved to the forefront of the vaccination efforts by the health department and Cayuga Health System. Thats taken shape in the form of rural pop-up clinics, informed by state data that breaks down vaccine rates by zip code, allowing county officials to see which municipalities are in need of either more access or more awareness.
Ultimately, were going to have to do some work to convince those folks that are on the fence that we really need them to get vaccinated, Kruppa said. One of the best ways we can do that is on a one-to-one basis with our family and friends and those in our circles to talk about our experiences having gotten vaccinated and why it was important to us to do it.
One idea that was under consideration was incentivizing receiving the vaccine. That wouldnt be an entirely novel concept, as states like West Virginia have instituted programs to distribute bonds to those who receive vaccinations. Months ago, Tompkins County had assessed providing some sort of financial compensation to the homeless population, primarily to encourage that particularly transient group to return for a second dose after 3 or 4 weeksbut the emergence of the single-shot Johnson & Johnson vaccine rendered that moot.
Still, Kruppa said it was one approach that county officials have kept on their mind, even if it might be logistically difficult, or look different than a traditional incentivization program.
Incentivizing is something that we definitely have to consider, and we certainly are, and itll depend on the populations and the vaccination numbers, Kruppa said, touting the lifestyle changes that could entice people to receive the vaccine, particularly as proof of COVID-19 vaccination becomes a larger factor in society. Were talking about that in a very targeted way. We need to incentivize vaccinations, but its not always something tangible like money or something to that effect. Theres reasons to be vaccinated beyond protecting yourself and those around you from potentially getting sick, particularly as we reopen.
There is, of course, a substantial amount of the population that isnt currently able to receive the vaccination. Only Pfizers vaccine has been approved for people 16 and over (as opposed to 18 and over for the other available vaccines), meaning that the supply is lessened for that group, and that no vaccines are available for people under 16 years old. That could partially change as soon as next week, but until it does, 10-12 percent of the countys population will remain unvaccinated through no choice of their own.
Independent of further eligibility expansion, Kruppa said this is clearly a different era of vaccine distribution in which it would be nonsensical to employ the same strategies that worked to vaccinate the first 50,000 or so residents of the county.
The days of doing 1,100-1,200 doses up at the mall are behind us, Kruppa acknowledged. Now weve got to get out to the community to get to people and make it as accessible as possible so we can get that next phase of individuals.
Vials labelled "COVID-19 Coronavirus Vaccine" and sryinge are seen in front of displayed Novavax logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
Novavax Inc (NVAX.O) said on Thursday it has agreed to start shipping doses of its COVID-19 vaccine candidate to the COVAX program in the third quarter of 2021 in an effort to deliver on its promise to provide 1.1 billion shots to the global vaccination program.
Novavax said it will manufacture and ship 350 million shots itself. India's Serum Institute (SII) will provide the remainder of the 1.1 billion shots to COVAX through a separate agreement.
The COVAX facility is a global initiative aimed at access to COVID-19 vaccines for poorer countries. It is co-led by GAVI, the World Health Organization and the Coalition for Epidemic Preparedness Innovations.
GAVI's chief executive, Seth Berkley, said in a statement that the deal is "a major step towards our goal of delivering 2 billion doses of safe and effective vaccines in 2021."
Novavax reached an preliminary agreement with COVAX in February to make and deliver 1.1 billion doses of its vaccine in partnership with SII.
Its shot has yet to be authorized by regulators in any country but it has posted late stage trial data that shows it is highly effective against the original variant of COVID-19 and a newer variant first found in Britain. read more
Novavax said it will get an upfront payment from GAVI later this month and an additional payment following an emergency use listing for its vaccine by the World Health Organization.
Reuters reported in March that Novavax delayed its supply agreements with the European Union because of production problems, including shortages of raw materials used in making its vaccine. read more Serum has also said that it was having difficulty obtaining the materials needed to make the Novavax vaccine.
Reuters reported earlier this week the company told the European Union it plans to begin delivering its COVID-19 vaccine candidate to the bloc towards the end of this year. read more
Our Standards: The Thomson Reuters Trust Principles.
Since the first Covid-19 vaccines were approved in December, the U.S. has administered nearly 250 million doses, getting shots in the arms of more than four in 10 Americans. About a third of the population is fully vaccinated.
Those numbers are far from what experts say is probably necessary to achieve herd immunity, the point at which enough people become immune such that the whole community is protected. And the average daily rate of vaccinations has fallen by almost a third from its peak in mid-April.
While those numbers are frustrating efforts to broaden the vaccinated population, the country does appear to have reached a tipping point in passing the 40% marka figure that many public-health experts call an important threshold where vaccinations gain an upper hand over the coronavirus.
Joel Eastwood contributed to this article.
